BPC-157 and TB-500 are research peptides. This article is for educational purposes only and does not constitute medical advice. Always consult a licensed physician before beginning any peptide protocol. These compounds are not FDA-approved for human use.
Both BPC-157 and TB-500 are among the most studied healing peptides available. Used alone, each produces meaningful tissue repair. Used together, they create a complementary dual-mechanism protocol that addresses healing from two distinct biological angles — making the combination significantly more powerful than either alone.
BPC-157 works locally — it concentrates repair activity in the specific tissue where it's injected, driving angiogenesis, receptor upregulation, and mucosal healing. TB-500 works systemically — it circulates throughout the body, promoting actin polymerization in damaged cells, cellular migration to injury sites, and broad anti-inflammatory action.
Think of it this way: BPC-157 sends the construction crew to the building site. TB-500 supplies the raw materials from the warehouse.
| Full Name | Body Protection Compound 157 |
|---|---|
| Source | Derived from a protective protein found in human gastric juice |
| Half-Life | ~4 hours (injectable); longer with oral administration for gut-specific effects |
| Primary Mechanisms | VEGFR2 upregulation, EGF pathway activation, nitric oxide system modulation, angiogenesis, tendon-to-bone healing acceleration |
| Best For | Tendons, ligaments, gut lining, muscle tears, joint cartilage, bone healing, post-surgical recovery |
| Standard Dose | 250–500 mcg/day SubQ, near injury site |
| Route | SubQ injection (systemic), oral (gut-specific only), intranasal (emerging) |
BPC-157 is a 15-amino-acid peptide derived from a naturally occurring protein in human gastric juice. It has been the subject of over 80 animal studies and a growing body of human case data showing extraordinary healing acceleration across virtually every tissue type.
Its most powerful mechanism is upregulation of VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) — which drives new blood vessel formation into injured tissue. Without adequate blood supply, tissue cannot heal. BPC-157 essentially fast-tracks the vascularization process that normally limits recovery speed.
It also modulates the nitric oxide system — important for reducing the excessive inflammation that causes secondary tissue damage after injury — and directly activates growth factor signaling pathways (EGF, FGF) that trigger cell proliferation and collagen synthesis in tendons and ligaments.
| Full Name | Thymosin Beta-4 (synthetic fragment) |
|---|---|
| Source | Synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide |
| Half-Life | Longer than BPC-157; once or twice weekly dosing is effective |
| Primary Mechanisms | Actin sequestration/upregulation, cellular migration (G-actin binding), anti-inflammation, angiogenesis, stem cell mobilization |
| Best For | Systemic inflammation, muscle tears, cardiac tissue, tendon injuries, neurological healing, hair loss (emerging) |
| Standard Dose | 2–5 mg, 2x per week SubQ or IM |
| Route | SubQ injection (preferred) or IM |
TB-500 is a synthetic version of the active region of Thymosin Beta-4 — a 43-amino-acid peptide found in virtually all human and animal cells. Its primary mechanism is binding to G-actin, the monomeric form of actin, which regulates cell shape, migration, and the cytoskeletal dynamics that underlie tissue repair.
When tissue is damaged, repair cells need to migrate to the injury site and reorganize their internal structure to begin rebuilding. TB-500 facilitates both of these processes systemically — meaning it can promote healing in tissues far from the injection site, which makes it fundamentally different from BPC-157's more localized action.
TB-500 also promotes stem cell mobilization from bone marrow into circulation, providing a fresh supply of undifferentiated cells that can be recruited to injured tissue — a mechanism with implications for injuries in poorly-vascularized areas like tendons and cartilage.
BPC-157 builds the vascular infrastructure the injury needs (new blood vessels, growth factor signaling). TB-500 populates that infrastructure with the repair cells (stem cells, migrating fibroblasts) that actually rebuild the tissue. Together they address both the supply side and the demand side of tissue regeneration simultaneously.
Both peptides arrive as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before injection. Never use regular sterile water — it doesn't contain the benzyl alcohol preservative that allows multi-dose use.
BPC-157 5mg vial + 2mL BAC water:
0.1mL (10 units) = 250mcg | 0.2mL (20 units) = 500mcg
TB-500 5mg vial + 2mL BAC water:
0.1mL (10 units) = 250mcg | 0.4mL (40 units) = 1,000mcg (1mg) | 0.8mL (80 units) = 2mg
| Peptide | Phase | Dose | Frequency | Duration |
|---|---|---|---|---|
| BPC-157 | Loading | 500 mcg | Once daily | Weeks 1–4 |
| BPC-157 | Maintenance | 250 mcg | Once daily | Weeks 5–8 |
| TB-500 | Loading | 5 mg | 2x per week | Weeks 1–4 |
| TB-500 | Maintenance | 2 mg | 2x per week | Weeks 5–8 |
BPC-157's local mechanism means injecting close to the injury produces superior results compared to distal injection. You're not injecting into the injury itself — you're injecting into the subcutaneous tissue surrounding it, typically 2–4 cm from the affected structure.
Because TB-500 works systemically via blood circulation, injection site location is not clinically significant. Standard injection sites are used for convenience and to distribute tissue stress:
Rotate injection sites every dose to prevent scar tissue buildup and subcutaneous nodules. Keep a written log of which site you used each day. Never inject into the same spot more than twice per week.
Neither BPC-157 nor TB-500 causes receptor downregulation in the way that peptide hormones like CJC-1295 do. However, cycling remains best practice for several reasons:
| Injury Type | Expected Duration | Cycle Recommendation |
|---|---|---|
| Acute muscle tear (<2 weeks old) | 4–6 weeks | One full cycle; reassess |
| Chronic tendon injury (3+ months) | 8–12 weeks | Full loading + maintenance; 8-week off, repeat if needed |
| Post-surgical recovery | 8–12 weeks | Begin 2 weeks post-op if cleared by surgeon |
| Gut healing (IBD, leaky gut) | 4–8 weeks | BPC-157 oral only; cycle 8 on, 4 off |
| Joint cartilage (mild–moderate) | 12+ weeks | Multiple cycles with 4-week breaks between |
The BPC-157 + TB-500 stack has documented or strongly mechanistically supported efficacy for:
| Condition | Primary Peptide | Evidence Level |
|---|---|---|
| Tendon tears & tendinopathy | BPC-157 (primary) + TB-500 | High (animal), Moderate (human case) |
| Ligament sprains & tears | BPC-157 (primary) + TB-500 | High (animal), Moderate (human case) |
| Muscle strains & tears | TB-500 (primary) + BPC-157 | High (animal), Moderate (human case) |
| Post-surgical tissue repair | Both equally | Moderate (animal), Emerging (human) |
| Gut healing (IBD, leaky gut) | BPC-157 oral (primary) | High (animal), Moderate (human case) |
| Joint cartilage degradation | BPC-157 (primary) | Moderate (animal), Low-Moderate (human) |
| Bone fractures | BPC-157 (primary) | High (animal), Limited (human) |
| Chronic inflammation | TB-500 (primary) + BPC-157 | Moderate |
Both peptides have favorable safety profiles based on available research:
Avoid combining BPC-157 with NSAIDs (ibuprofen, naproxen) during active use — NSAIDs suppress the prostaglandin and COX pathways that BPC-157 partly relies on to drive healing. Consider replacing NSAIDs with low-dose aspirin or curcumin if pain management is needed during the protocol.
Most users report the first signs of reduced inflammation and improved pain within 7–14 days of the loading phase. Structural improvements — measurable range of motion, strength recovery, and imaging changes — typically appear at weeks 4–8. Chronic injuries that have been present for years may take multiple full cycles.
Oral BPC-157 is effective specifically for gut and gastrointestinal conditions (IBD, leaky gut, ulcers, SIBO recovery). For musculoskeletal injuries, systemic bioavailability via the oral route is likely insufficient — SubQ injection near the injury site is required for meaningful musculoskeletal healing effects.
Most practitioners cycle 8 weeks on, 4–8 weeks off. Unlike GH secretagogues, there is no confirmed receptor desensitization with BPC-157. Cycling is recommended primarily to assess progress and as a precautionary measure given limited long-term human data.
Yes. Common additions include Thymosin Alpha-1 for immune support (especially in chronic infections contributing to injury persistence), CJC-1295/Ipamorelin for GH-mediated systemic recovery, and GHK-Cu (copper peptide) topically over the injury site for additional collagen synthesis support.
Quality is the most important variable in peptide efficacy. Purity varies enormously across suppliers. Always source from vendors that provide mass spectrometry (MS) and HPLC-verified Certificates of Analysis (COA) with ≥98% purity. The Emerald Wellness verified vendor directory (available to members) only lists COA-verified suppliers.
Log both peptides, get real-time interaction checking, follow your injection site rotation schedule, and let the Health Intelligence Advisor optimize your healing protocol based on injury type and response. Founding member pricing locked at launch.
Join the Waitlist →